Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1.
about
Genes that induce immunity--DNA vaccines.DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.Innate endogenous adjuvants prime to desirable immune responses via mucosal routesAugmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys.DNA vaccines against human immunodeficiency virus type 1 in the past decade.Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants.The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses.Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.The potential of topical DNA vaccines adjuvanted by cytokines.Cholera toxin B subunit acts as a potent systemic adjuvant for HIV-1 DNA vaccination intramuscularly in mice.Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen.Modulation of HIV-1 immunity by adjuvants.Cytokines: the future of intranasal vaccine adjuvants.Recent Developments in Preclinical DNA Vaccination.Antigen fusion with C3d3 augments or inhibits humoral immunity to AAV genetic vaccines in a transgene-dependent manner.Effect of cytokine-encoding plasmid delivery on immune response to Japanese encephalitis virus DNA vaccine in mice.Co-expression of S. Typhi GroEL and IL-22 gene augments immune responses against Salmonella infection.8 Br-cAMP enhances both humoral and cell-mediated immune responses induced by an HIV-1 DNA vaccine.
P2860
Q33641393-455C205B-F519-4A40-99CD-5E35CF51F44FQ33843297-2B0D5B98-C5AF-4EF3-87A4-7F7E09A708C0Q35143128-265DF0F1-673E-46C7-94AB-0E30AC568B81Q35674907-93D31C85-2C6D-41A8-B5C4-8F83D2D962F5Q35745831-560F11CE-F98B-479A-AC42-BE4271EEFE8EQ35826378-30C10B18-FF57-4FB8-A5B8-80909FDB58A0Q35951849-B7F10DF9-77AA-4819-B2AE-E57204615431Q36144729-17CE7DC8-5EA3-4E83-B070-C4FD4D2372D9Q36960508-F89C8095-A4C6-42C4-A26E-46541CFDD0A4Q36977797-92C5DCB3-BDDE-4935-AF1B-5BD785149486Q37412508-5F521BCD-E802-42BC-8D0C-BFF7F3610F85Q37698564-1EF9FBDB-BBD0-4543-9E4A-42C8B224B879Q37914007-9A74DA91-5A1F-40EE-88D3-4D15D604DCE2Q38581976-4BF10262-0FFB-4902-A32F-2E7152B5C088Q39771124-0AD1ED67-0051-49AE-9AEE-83DC3DB220A4Q42991960-D14F7190-2E69-4805-991A-0B5862388B76Q43855252-E0CBEB34-D799-433E-ACEE-E4CECC5ACEF8Q45867374-110C47DF-C977-46C5-A555-BC4E7B429939
P2860
Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Intranasal administration of h ...... diated immunity against HIV-1.
@en
Intranasal administration of human immunodeficiency virus type-1
@nl
type
label
Intranasal administration of h ...... diated immunity against HIV-1.
@en
Intranasal administration of human immunodeficiency virus type-1
@nl
prefLabel
Intranasal administration of h ...... diated immunity against HIV-1.
@en
Intranasal administration of human immunodeficiency virus type-1
@nl
P2093
P2860
P1433
P1476
Intranasal administration of h ...... diated immunity against HIV-1.
@en
P2093
Fukushima J
Hamajima K
Kawamoto S
Shapshak P
P2860
P304
P356
10.1046/J.1365-2567.1998.00533.X
P577
1998-07-01T00:00:00Z